Pharmosa Biopharm Inc. (TPEX:6875)
Taiwan · Delayed Price · Currency is TWD 51.50
-1.90 (-3.56%)
Oct 31, 2025, 2:31 PM CST
Pharmosa Biopharm Revenue
Pharmosa Biopharm had revenue of 15.68M TWD in the quarter ending June 30, 2025, with 64.31% growth. This brings the company's revenue in the last twelve months to 173.63M, down -46.43% year-over-year. In the year 2024, Pharmosa Biopharm had annual revenue of 167.57M, down -46.72%.
Revenue (ttm)
173.63M
Revenue Growth
-46.43%
P/S Ratio
38.29
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 167.57M | -146.93M | -46.72% |
| Dec 31, 2023 | 314.50M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bora Pharmaceuticals Co., LTD. | 21.32B |
| Lotus Pharmaceutical | 19.12B |
| PharmaEssentia | 12.63B |
| Pegavision | 6.90B |
| Center Laboratories | 1.60B |
| Oneness Biotech | 112.57M |
| Polaris Group | 64.02M |
| Caliway Biopharmaceuticals | 44.83M |